Tait M J, Petrik V, Loosemore A, Bell B A, Papadopoulos M C
Academic Neurosurgery Unit, St George's University of London, London, UK.
Br J Neurosurg. 2007 Oct;21(5):496-500. doi: 10.1080/02688690701449251.
Glioblastoma is the most common primary brain tumour. The aim of this study was to determine trends in survival over a 12-year period. Survival data were collected retrospectively for 625 patients who had surgery for histologically-confirmed glioblastoma between 1993 and 2004 in a single centre. Data including age, sex, preoperative Karnofsky performance score, tumour site, date of surgery, and type of surgical and adjuvant treatment were collected. Overall median survival was 189 days; there was no significant change in survival over 12 years. Multivariate analysis identified the following independent positive prognostic factors: age <60 years (p < 0.0005), Karnofsky score > or = 70 (p < 0.0001), tumour debulking, rather than biopsy (p < 0.001), right-sided lesion (p < 0.05), unilateral tumour (p < 0.05) and radiotherapy (p < 0.0001). Despite neurosurgical advances, the survival of patients with glioblastoma has not changed for more than a decade. Although, overall, glioblastoma has a short survival, our data show that individual patient survival is heterogeneous.
胶质母细胞瘤是最常见的原发性脑肿瘤。本研究的目的是确定12年间的生存趋势。对1993年至2004年在单一中心接受手术治疗且组织学确诊为胶质母细胞瘤的625例患者的生存数据进行回顾性收集。收集的数据包括年龄、性别、术前卡诺夫斯基表现评分、肿瘤部位、手术日期以及手术和辅助治疗类型。总体中位生存期为189天；12年间生存率无显著变化。多变量分析确定了以下独立的阳性预后因素：年龄<60岁（p<0.0005）、卡诺夫斯基评分≥70（p<0.0001）、肿瘤大部切除而非活检（p<0.001）、右侧病变（p<0.05）、单侧肿瘤（p<0.05）和放疗（p<0.0001）。尽管神经外科技术有所进步，但胶质母细胞瘤患者的生存率十多年来并未改变。虽然总体而言，胶质母细胞瘤的生存期较短，但我们的数据表明个体患者的生存期存在异质性。
